Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Shorted: Short Interest Up 8,308.0% in October

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 818,602 shares, a growth of 8,308.0% from the September 30th total of 9,736 shares. Based on an average daily volume of 30,928,638 shares, the days-to-cover ratio is currently 0.0 days. Approximately 29.5% of the company’s shares are sold short.

Alaunos Therapeutics Trading Down 6.6%

Shares of NASDAQ TCRT traded down $0.15 during mid-day trading on Monday, reaching $2.13. The company had a trading volume of 533,577 shares, compared to its average volume of 2,351,774. The stock has a market cap of $7.05 million, a price-to-earnings ratio of -1.12 and a beta of -0.87. Alaunos Therapeutics has a 52 week low of $0.72 and a 52 week high of $4.50. The business’s 50-day moving average is $1.62 and its 200-day moving average is $2.09.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.

The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations.